Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and
dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal
antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and
spread. Drugs used in chemotherapy, such as ixazomib and dexamethasone, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving daratumumab, ixazomib, and dexamethasone
may be effective in treating participants with light chain amyloidosis.